ArticleAmerican journal of otolaryngology
Repurposing 0.5% povidone iodine solution in otorhinolaryngology practice in Covid 19 pandemic.
Article in American journal of otolaryngology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04894409 (Evaluation of Silver Nanoparticles as an Oropharyngeal Product), which is not on this map. Cited by 29 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Evaluation of Silver Nanoparticles as an Oropharyngeal Product (Mouthwash) and Nasal Hygiene, by Health Personnel Working at the Tijuana General Hospital Exposed to Patients Diagnosed With Atypical Pneumonia Caused by SARS-CoV-2
Who cites it
29 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Effectiveness of mouthwashes on reducing SARS-CoV-2 viral load in oral cavity: a systematic review and meta-analysis.BMC oral health · 2023Pooled it
- Efficacy of Mouth Rinses and Nasal Spray in the Inactivation of SARS-CoV-2: A Systematic Review and Meta-Analysis ofInternational journal of environmental research and public health · 2022Pooled it
- Evaluation of silver nanoparticles for the prevention of SARS-CoV-2 infection in health workers: In vitro and in vivo.PloS one · 2021Trial
- Intranasal povidone-iodine concentration and olfactory recovery after endoscopic endonasal pituitary surgery.Pituitary · 2026Article
- A review of advancements in antiseptics for wound care in diabetic and non-diabetic patients.Journal of diabetes and metabolic disorders · 2025Review
- Antiseptics: An expeditious third force in the prevention and management of coronavirus diseases.Current research in microbial sciences · 2024Review
- Efficacy of different mouthwashes against COVID-19: A systematic review and network meta-analysis.The Japanese dental science review · 2023Review
- Preprocedural Viral Load Effects of Oral Antiseptics on SARS-CoV-2 in Patients with COVID-19: A Systematic Review.Biomedicines · 2023Review
- Stable thyroid function despite regular use of povidone-iodine throat spray for SARS-CoV-2 prophylaxis.Annals of medicine · 2022Article
- Yogic Neti-Kriya Using Povidone Iodine: Can it have a Preventive Role Against SARS-CoV-2 Infection Gateway?Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Povidone Iodine (PVP-I) Oro-Nasal Spray: An Effective Shield for COVID-19 Protection for Health Care Worker (HCW), for all.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Effect of 0.5% povidone-iodine on the nasopharyngeal and oropharyngeal viral loads in patients with COVID-19: A double-blind placebo-controlled randomized clinical trial.Journal of family medicine and primary care · 2022Article
- Virucidal Effect of Povidone Iodine on SARS-CoV-2 in Nasopharynx: An Open-label Randomized Clinical Trial.Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India · 2022Article
- Oral Antiseptics against SARS-CoV-2: A Literature Review.International journal of environmental research and public health · 2022Review
- In vitro inactivation of SARS-CoV-2 using a povidone-iodine oral rinse.BMC oral health · 2022Article
- Changes in reverse transcription polymerase chain reaction cycle threshold values of SARS-CoV-2 with topical povidone iodine use: A single-arm open-label interventional study.Journal of family medicine and primary care · 2022Article
- Oral hygiene practices in the pandemic- Evidence-based discussion of 8 common issues.Journal of family medicine and primary care · 2022Article
- Thermosensitive Poly(DHSe/PEG/PPG Urethane)-Based Hydrogel Extended Remdesivir Application in Ophthalmic Medication.Pharmaceutics · 2021Article
- In vitro comparison of the tensile strength of elastomeric ligatures exposed to Povidone Iodine 1%, Chlorhexidine 0.02%, and hydrogen peroxide 5.International orthodontics · 2021Article
- In Vitro Evaluation of the Virucidal Activity of Different Povidone-Iodine Formulations Against Murine and Human Coronaviruses.Infectious diseases and therapy · 2021Article
Corrections and comments
- Commented on by
Authors and funding
3 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
SARS CoV 2 is very much homologous in structure to SARS CoV. Review of literature suggests the in-vitro virucidal action of povidone iodine in SARS CoV and MERS. The oropharynx and nasopharynx are target sites of SARS CoV 2. A significant proportion of COVID 19 sufferers are asymptomatic, but shedding these viral particles, PVP-I has been shown to be a safe therapy when used as a mouthwash or taken nasally or used during ophthalmic surgeries.
aimsMATERIALS AND
methods0.5% PVP-I solution is prepared from commercially available 10% PVP-I solution. Patients were instructed to put 0.5% PVP-I drops in nose and rinse mouth with gargle prior examinations for 30 s. For endoscopic procedure (nasal and throat) nasal douching and gargling to be started one day prior. Douching and rinsing to be repeated just before procedures. Nasal packing with 0.5% PVP-I along with 4% xylocaine/adrenaline solution, tolerability and any allergic reaction noted.
resultsThe patient and health care workers tolerated the 0.5%. No allergy was noted.
conclusionWe propose the use of 0.5% PVP-I in healthcare workers and their patients to minimise the risk of spread of the disease in addition to the recommended PPE.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.